Form 4: RA Capital Acquires 3.25 Million Pre-Funded Warrants in 89bio, Inc.

RA Capital Management and related entities acquired 3.25 million pre-funded warrants in 89bio, Inc., convertible into common stock, increasing their beneficial ownership.

Summary

• RA Capital Management, L.P., along with related entities, has acquired 3,250,000 pre-funded warrants of 89bio, Inc.
• These warrants are immediately exercisable and have no expiration date.
• Each warrant can be converted into one share of common stock at a price of $0.001.
• The transaction occurred on November 14, 2024.
• Following the transaction, RA Capital and related entities beneficially own 4,331,081 shares of 89bio, Inc. common stock.
• The warrants cannot be exercised if it would cause the holder to own more than 9.99% of the outstanding common stock.

Sentiment

Score: 7

Explanation: The document indicates a positive investment by a major healthcare fund, suggesting confidence in the company's future. However, the complex ownership structure and limitations on warrant exercise prevent a higher score.

Positives

• The acquisition of pre-funded warrants indicates a strong investment by RA Capital in 89bio, Inc.
• The immediate exercisability of the warrants provides flexibility for RA Capital.
• The lack of an expiration date on the warrants provides long-term investment potential.

Risks

• The warrants cannot be exercised if it would cause RA Capital to exceed 9.99% ownership, potentially limiting their upside.
• The disclaimer of beneficial ownership by certain individuals may indicate a complex ownership structure.

Management Comments

• Dr. Peter Kolchinsky and Mr. Rajeev Shah disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest therein.
• Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.

Industry Context

This transaction is a common occurrence in the biotech industry where investment firms often use warrants to gain exposure to potential upside in companies they believe in. RA Capital is a well-known healthcare investment firm, so this move is consistent with their investment strategy.

Comparison to Industry Standards

• The use of pre-funded warrants is a common practice in biotech financing, allowing investors to participate in potential future growth.
• RA Capital's investment is similar to other institutional investments in biotech companies, where firms often take significant positions through various financial instruments.
• The 9.99% ownership cap is a standard clause to avoid triggering certain regulatory thresholds.

Stakeholder Impact

• The acquisition of warrants by RA Capital may be viewed positively by shareholders, potentially increasing investor confidence.
• The transaction could lead to increased scrutiny of 89bio, Inc. by other investors.

Key Dates

Keywords

RA Capital Management, 89bio, Inc., Pre-Funded Warrants, Beneficial Ownership, Investment, Securities, Common Stock